PHIL DOBSON, BVetMed MRCVS
Phil qualified as a Veterinary Surgeon from the Royal Vet College London. After short spells in academia and in practice he joined Ciba-Geigy Animal Health (which became Novartis). He spent over twenty years in various posts in R+D including global head of clinical development. Phil left Novartis in 2008 and has been an independent consultant to animal health companies since that time. Phil has worked on most areas of therapeutics and in most domestic species over the years but has a special interest in anti-parasitics. Phil is married to another vet and has two daughters who are also vets.
PHILIP GOELET PH.D. Executive Chairman
Philip has extensive experience as a scientist, entrepreneur and investor. His scientific career started at the Laboratory of Molecular Biology (LMB, Cambridge UK) under the supervision of Jon Karn in the laboratory of Sydney Brenner, where he sequenced tobacco mosaic virus as part of his PhD at the University of Cambridge. He then pursued postdoctoral research in neuroscience at Columbia University with Nobel Laureate Eric Kandel. Prior co-founding Chalante and Acidophil, Philip co-founded and managed Molecular Tool (Baltimore, MD: pioneering single nucleotide polymorphism analysis, acquired by Orchid Biosciences) and RiboTargets (Cambridge UK: therapeutics based upon targeting RNA, merged with Vernalis). In parallel to co-founding Acidophil with Sydney Brenner, Philip co-founded Red Abbey Venture Partners, a health care private equity fund with Frank Bonsal and Matt Zuga.
MARK TREHERNE PH.D.
Mark is an investor, fundraiser and research scientist with 30 years' experience in the discovery and development of novel disease treatments. After an academic career in Switzerland, he became responsible for research into neurodegenerative diseases at Pfizer, UK, until 1997. On leaving Pfizer, he set up Cambridge Drug Discovery as Chief Executive, which was then sold to BioFocus in 2001 and is now part of Charles River. Since then, Mark has helped raise over £150 million for various early-stage biotechnology companies and taken some of them through to exit by trade sale or IPO. He has now served on the boards of 16 private and public companies over the last 15 years and worked for the UK Government until 2016. He has a PhD in Pharmacology from Cambridge University, which was awarded in 1987.
SCIENTIFIC ADVISORY GROUP
ELIZABETH FARRANT, PH.D.
Elizabeth is the CEO of New Path Molecular Research, which she founded with Prof Steven Ley and Dr Nikzad Nikbin of Cambridge University. New Path is an innovation partner in synthetic chemistry and machine assisted synthesis, developing intellectual property for its collaborators in crop science, human and animal health and fine chemicals. Prior to New Path Elizabeth has a twenty year track record in chemistry research and innovation, working for SmithKline Beecham, GSK and Pfizer. She has a degree in chemistry and a PhD in natural product synthesis and is a published expert in medicinal chemistry, flow chemistry, automation and lead diversification.
STEVEN MOSS, PH.D.
Steven is the Chief Technology Officer of Isomerase Therapeutics. He co-founded Isomerase Therapeutics in 2013 and is highly practiced in natural products chemistry - including process optimisation, synthetic biology, semi-synthesis and analytical chemistry. In particular, Steven is experienced in applying Isomerase's bioengineering platform and semi-synthesis to generate microbial natural products with characteristics more suited for the intended use than the parent, and taking these discoveries through into manufacturing. Steven has worked with a number of different organisations through Isomerase to solve natural products challenges. From 2009 until 2013, Steven was the Director of Natural Products Chemistry at Biotica Technology, where he was responsible for fermentation and chemistry as well as the management and technology transfer associated with outsourced manufacture and chemistry. Steven joined Biotica in 2002 as a Research Scientist and worked on a number of different microbial natural product based programmes across multiple therapeutic areas. Prior to that, he spent two years as a Post-Doctoral Research Associate with Professor Heinz G. Floss (University of Washington, Seattle). Steven holds a BSc and PhD in Chemistry from the University of Durham and he is an author or inventor on over 50 scientific papers and US/EU patents.
PROF. DAVID SPRING, D.PHIL.
David is currently a Professor at the University of Cambridge within the Chemistry Department. He worked with Sir Jack E. Baldwin (University of Oxford) and Stuart L. Schreiber (Harvard University), before he joined the faculty at the University of Cambridge in 2001. David's research spans the disciplines of chemistry and biology through the synthesis of small molecules, which are applied to problems in the life sciences. In particular, he has focused on diversity-oriented synthesis, new synthetic methodologies and chemical biology in order to discover new, biologically-functional small molecules. He has published six book chapters and co-authored more than 180 journal articles. His group's laboratory has been awarded a number of research prizes including the Royal Society of Chemistry's "Norman Heatley Award" and "Corday-Morgan Award", the Spanish Chemical Societies' "Felix Serratosa Award", the MedImmune Protein and Peptide Science Award, and Royal Society Wolfson Research Merit Award. He is a Fellow of the Royal Society of Chemistry (FRSC). He has collaborated with many international companies in the chemical industries.
ANDREW WEATHERLEY, PH.D.
Andrew has 25 years of experience in Research and Development of Veterinary Medicines with Pfizer Animal Health. A parasitologist by training, he has managed teams responsible for the development of a wide range of veterinary products including antiparasitic agents, antimicrobials, pain medications, livestock productivity enhancing agents and treatments for a range of metabolic diseases. As head of the Veterinary Research and Development department at Pfizer in the UK, Andrew was responsible for a group of nearly 200 scientists, veterinarians and regulatory affairs specialists. Together with a similar but larger organisation in the USA, the research and development organisation was responsible for providing new products to support global sales of over $2 billion. More recently Andrew has been responsible for developing the commercial portfolio of the Animal and Plant Health Agency (formerly the Central Veterinary Laboratories) and was Director for International Strategy at the Pirbright Institute. He is now a freelance consultant to the Animal Health Industry.
Mr. Adorf has a long and well-established career in life sciences companies that spans a number of global and regional management positions in large corporates. In the 1990s he was in AkzoNobel's medical diagnostics group and eventually led their regional business in South-East Asia. He also held various global management roles at Royal DSM, where his focus was on human nutrition ingredients for health. Most recently, Martijn Adorf was Managing Director of Nutreco's Business Unit Feed Additives (part of SHV) from 2013 until end 2017 and member of the Nutreco Executive Committee. He was responsible for significant global growth of the Selko feed additives business, focusing on reduction of antibiotics in livestock production, and the acquisition of Micronutrients in the USA. Mr. Adorf holds an MSc in biochemistry from the Radboud University, Nijmegen, in the Netherlands.
MARIE-PAUL LACHAUD, DVM
For the past 10 years, Dr. Lachaud has served the veterinary pharmaceutical industry as an experienced consultant, with a specific focus on international clinical development and regulatory procedures for animal prescription drugs. From 2000 to 2008, Dr. Lachaud was the European Animal Health Director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and Contract Research Organization dedicated to veterinary drug clinical development and regulatory affairs, which was acquired by ICON in 2000. Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine for years. Her work has resulted in significant companion animal health product approvals in Europe and the United-States in a number of innovative therapeutic areas, including reproduction, atopic dermatitis, chronic heart failure, wound healing, chronic kidney disease, osteoarthritis, perioperative pain, obesity, oncology, cognitive dysfunction and anxiety-related disorders. She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.
Martin is vice president and is the chief operating officer at Whitehead Institute for Biomedical Research. He previously served as: Vice President for Licensing, Georgetown University; Associate Vice President for Licensing, Case Western Reserve University; and, Senior Technology Licensing Manager and Interim Director, Office of Technology Licensing & Industry Sponsored Research, Harvard Medical School. Prior to arriving in the United States he held positions with IDA Ireland, Enterprise Ireland and Eli Lilly & Co. He holds both a bachelor's and master's degree in biochemistry from University College Cork, Ireland.